vs
OptimizeRx Corp（OPRX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
OptimizeRx Corp的季度营收约是REGENXBIO Inc.的1.1倍（$32.2M vs $30.3M），OptimizeRx Corp净利率更高（15.6% vs -221.3%，领先236.9%），REGENXBIO Inc.同比增速更快（43.0% vs -0.2%），OptimizeRx Corp自由现金流更多（$7.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 28.0%）
OptimizeRx Corp是一家总部位于美国的数字健康科技企业，为生命科学公司、医疗机构及药房合作伙伴提供患者参与、药物可负担性和临床沟通相关解决方案，核心产品包括数字购药优惠工具、患者支持项目等，助力提升药物可及性与用药依从性。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OPRX vs RGNX — 直观对比
营收规模更大
OPRX
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出43.2%
-0.2%
净利率更高
OPRX
高出236.9%
-221.3%
自由现金流更多
OPRX
多$59.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
28.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.2M | $30.3M |
| 净利润 | $5.0M | $-67.1M |
| 毛利率 | 74.8% | — |
| 营业利润率 | 26.6% | -190.0% |
| 净利率 | 15.6% | -221.3% |
| 营收同比 | -0.2% | 43.0% |
| 净利润同比 | 6535.9% | -31.2% |
| 每股收益（稀释后） | $0.27 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPRXRGNX
| Q4 25 | $32.2M | $30.3M | ||
| Q3 25 | $26.1M | $29.7M | ||
| Q2 25 | $29.2M | $21.4M | ||
| Q1 25 | $21.9M | $89.0M | ||
| Q4 24 | $32.3M | $21.2M | ||
| Q3 24 | $21.3M | $24.2M | ||
| Q2 24 | $18.8M | $22.3M | ||
| Q1 24 | $19.7M | $15.6M |
净利润OPRXRGNX
| Q4 25 | $5.0M | $-67.1M | ||
| Q3 25 | $779.0K | $-61.9M | ||
| Q2 25 | $1.5M | $-70.9M | ||
| Q1 25 | $-2.2M | $6.1M | ||
| Q4 24 | $-78.0K | $-51.2M | ||
| Q3 24 | $-9.1M | $-59.6M | ||
| Q2 24 | $-4.0M | $-53.0M | ||
| Q1 24 | $-6.9M | $-63.3M |
毛利率OPRXRGNX
| Q4 25 | 74.8% | — | ||
| Q3 25 | 67.2% | — | ||
| Q2 25 | 63.8% | — | ||
| Q1 25 | 60.9% | — | ||
| Q4 24 | 68.1% | 70.2% | ||
| Q3 24 | 63.1% | 48.8% | ||
| Q2 24 | 62.2% | 52.5% | ||
| Q1 24 | 62.0% | 72.6% |
营业利润率OPRXRGNX
| Q4 25 | 26.6% | -190.0% | ||
| Q3 25 | 7.9% | -176.3% | ||
| Q2 25 | 10.9% | -296.3% | ||
| Q1 25 | -9.6% | 13.6% | ||
| Q4 24 | 11.2% | -242.1% | ||
| Q3 24 | -40.2% | -256.6% | ||
| Q2 24 | -19.9% | -251.3% | ||
| Q1 24 | -25.5% | -408.8% |
净利率OPRXRGNX
| Q4 25 | 15.6% | -221.3% | ||
| Q3 25 | 3.0% | -208.3% | ||
| Q2 25 | 5.2% | -331.8% | ||
| Q1 25 | -10.0% | 6.8% | ||
| Q4 24 | -0.2% | -241.3% | ||
| Q3 24 | -42.8% | -246.3% | ||
| Q2 24 | -21.3% | -237.7% | ||
| Q1 24 | -35.0% | -405.4% |
每股收益（稀释后）OPRXRGNX
| Q4 25 | $0.27 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $0.08 | $-1.38 | ||
| Q1 25 | $-0.12 | $0.12 | ||
| Q4 24 | $0.00 | $-0.99 | ||
| Q3 24 | $-0.50 | $-1.17 | ||
| Q2 24 | $-0.22 | $-1.05 | ||
| Q1 24 | $-0.38 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $230.1M |
| 总债务越低越好 | $26.3M | — |
| 股东权益账面价值 | $128.3M | $102.7M |
| 总资产 | $176.9M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资OPRXRGNX
| Q4 25 | $23.4M | $230.1M | ||
| Q3 25 | $19.5M | $274.2M | ||
| Q2 25 | $16.6M | $323.3M | ||
| Q1 25 | $16.6M | $267.9M | ||
| Q4 24 | $13.4M | $234.7M | ||
| Q3 24 | $16.1M | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务OPRXRGNX
| Q4 25 | $26.3M | — | ||
| Q3 25 | $28.8M | — | ||
| Q2 25 | $29.3M | — | ||
| Q1 25 | $33.8M | — | ||
| Q4 24 | $34.3M | — | ||
| Q3 24 | $36.8M | — | ||
| Q2 24 | $37.3M | — | ||
| Q1 24 | $37.8M | — |
股东权益OPRXRGNX
| Q4 25 | $128.3M | $102.7M | ||
| Q3 25 | $122.3M | $161.5M | ||
| Q2 25 | $119.3M | $213.7M | ||
| Q1 25 | $116.3M | $274.2M | ||
| Q4 24 | $117.0M | $259.7M | ||
| Q3 24 | $114.5M | $301.4M | ||
| Q2 24 | $121.0M | $348.3M | ||
| Q1 24 | $122.5M | $390.7M |
总资产OPRXRGNX
| Q4 25 | $176.9M | $453.0M | ||
| Q3 25 | $170.3M | $525.2M | ||
| Q2 25 | $169.3M | $581.0M | ||
| Q1 25 | $167.8M | $490.9M | ||
| Q4 24 | $171.2M | $466.0M | ||
| Q3 24 | $165.2M | $519.1M | ||
| Q2 24 | $172.9M | $569.4M | ||
| Q1 24 | $176.4M | $629.2M |
负债/权益比OPRXRGNX
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $7.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 22.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.41× | — |
| 过去12个月自由现金流最近4个季度 | $18.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流OPRXRGNX
| Q4 25 | $7.1M | $-52.3M | ||
| Q3 25 | $3.2M | $-56.0M | ||
| Q2 25 | $4.6M | $-49.3M | ||
| Q1 25 | $3.9M | $33.6M | ||
| Q4 24 | $198.0K | $-31.6M | ||
| Q3 24 | $1.8M | $-40.5M | ||
| Q2 24 | $782.0K | $-45.5M | ||
| Q1 24 | $2.1M | $-55.5M |
自由现金流OPRXRGNX
| Q4 25 | $7.1M | $-52.8M | ||
| Q3 25 | $3.2M | $-56.5M | ||
| Q2 25 | $4.6M | $-49.7M | ||
| Q1 25 | $3.8M | $32.6M | ||
| Q4 24 | $181.0K | $-32.7M | ||
| Q3 24 | $1.8M | $-40.9M | ||
| Q2 24 | $737.0K | $-46.0M | ||
| Q1 24 | $2.1M | $-56.0M |
自由现金流率OPRXRGNX
| Q4 25 | 22.0% | -174.0% | ||
| Q3 25 | 12.2% | -189.9% | ||
| Q2 25 | 15.6% | -232.8% | ||
| Q1 25 | 17.5% | 36.6% | ||
| Q4 24 | 0.6% | -154.2% | ||
| Q3 24 | 8.3% | -168.9% | ||
| Q2 24 | 3.9% | -206.2% | ||
| Q1 24 | 10.6% | -358.5% |
资本支出强度OPRXRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率OPRXRGNX
| Q4 25 | 1.41× | — | ||
| Q3 25 | 4.11× | — | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPRX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
